Coksuer, H.Ozcura, F.Oghan, F.Haliloglu, B.Coksuer, C.2024-07-122024-07-1220111369-713710.3109/13697137.2010.5397242-s2.0-79960444173https://dx.doi.org/10.3109/13697137.2010.539724https://hdl.handle.net/20.500.12415/7851Background Hormones may have an impact on the incidence and course of dry-eye syndrome, and also nasal obstruction, especially in postmenopausal women. The aim of this study was to investigate the effects of drospirenone 2 mg + estradiol 1 mg (Angeliq (R), Bayer AG, Berlin, Germany) on ocular functions and nasal airflow in postmenopausal women. Methods Thirty-four postmenopausal women were recruited for the study. A questionnaire on ocular surface disease index (OSDI) was administered; after routine ophthalmologic examination, tear film break-up time (TBUT) and Schirmer tests were performed. Intraocular pressure was measured with a Goldmann applanation tonometer. Nasal airflow resistance values were measured using rhinomanometry. Participants were submitted to oral daily treatment with drospirenone 2 mg + estradiol 1 mg. The duration of the study was 6 months and the participants were studied in the basal condition and after 6 months of therapy. Results The OSDI score and intraocular pressure were significantly higher before treatment than after treatment (p < 0.001); however, the results of the TBUT and Schimer test were significantly lower (p < 0.05). Rhinomanometric values were better during drospirenone 2 mg vertical bar estradiol 1 mg therapy than those observed at baseline (p < 0.001). Conclusions Oral daily treatment with drospirenone 2 mg + estradiol 1 mg reduces the risks for ocular diseases and nasal obstruction in postmenopausal women.eninfo:eu-repo/semantics/closedAccessHORMONE REPLACEMENT THERAPYDROSPIRENONEANGELIQDRY EYEOCULAR DISEASENASAL AIRFLOWArticle487421281244Q248214WOS:000292779500012Q2